Register

Cardiology

Cardiac Electrophysiology   

Questions discussed in this category

What continuous duration of device defined atrial fibrillation burden warrants initiation of anticoagulation if the patient qualifies by CHA2DS2-vasc score?
2 Answers available
What is your preferred method for subclinical CAD screening prior to initiation of class IC antiarrhythmic drugs for atrial fibrillation?
2 Answers available
In male patients in their 60s who had a single episode of PAF (24 hours, terminated spontaneously or with beta-blockers) without recurrence on 30-day monitoring, and without reversible triggers (such as OSA), should lifelong anticoagulation be started when they turn 65, thereby, increasing the CHA2DS2 VASc score to 1?
1 Answer available
What are your top takeaways from ACC 2024?
3 Answers available
In people who have had a single detected episode of atrial fibrillation, but none documented subsequently, is there any consideration for increased thrombolembolic risk just from altered atrial architecture, impaired contractility?
1 Answer available
Would you consider lifelong versus short-term (i.e. several months) course of anticoagulation for patients with elevated CHADSVASc score presenting with newly diagnosed paroxysmal atrial fibrillation triggered in the setting of acute illness (i.e. tachyarrhythmias with COVID-19 or bacterial pneumonia)?
2 Answers available
Which factors would prompt empirical lead extraction in bacteremic patients without TEE evidence of lead vegetation?
1 Answer available
How soon following pacemaker implantation can patients safely undergo elective cardioversion?
2 Answers available
In patients with concurrent, CAD and atrial fibrillation, more than 1 year post-PCI, the most recent AHA/ACC guidelines state that “oral anticoagulation monotherapy is recommended over the continuation of oral anticoagulant therapy and a single antiplatelet therapy.” If this individual undergoes surgery, the anticoagulant will be held. Would you then bridge with aspirin?
Joglar et al., PMID 38033089
1 Answer available
What are your criteria for deciding if a patient who had VF arrest in the setting of subacute myocarditis requires ICD or long term WCD?
1 Answer available
For patients who have undergone ablation for atrial fibrillation with elevated bleeding risk, what is your risk/benefit approach when deciding to continue oral anticoagulation long-term?
1 Answer available
What are some device parameters and clinical scenarios in which recommendations should be made to deactivate the LV lead in patients with an existing CRT-D device following LVAD implantation?
1 Answer available
When would you consider offering PVC ablation for otherwise healthy patients with preserved LV systolic function?
If PVC burden exceeded 10-15%, would you offer ablation in the absence of specific symptoms?  
1 Answer available
In light of the NOAH-AFNET6 and ARTESiA trials, how would you approach the decision regarding anticoagulation for patients with incidentally-detected AF <24 hrs on pacemakers/defibrillators?
How would you balance the stroke risk against the bleeding risk? And how would the AF burden play into your decision- would you treat 6 minutes of AF ...
1 Answer available
What is your preferred method for subclinical CAD screening prior to initiation of class IA antiarrhythmic drugs for atrial fibrillation?
1 Answer available
Would you initiate anti-arrhythmic drug therapy in patients who are asymptomatic and have normal LV function but with a PVC burden > 20 percent?
2 Answers available
Can sotalol initiation for atrial fibrillation be performed safely outpatient, and if so, what would be a reasonable protocol for implementing this? 
Can sotalol initiation for atrial fibrillation be performed safely outpatient, and if so, what would be a reasonable approach to accomplishing this?&n...
1 Answer available
Should systemic anticoagulation be considered for patients with a less than 1% atrial fibrillation burden on outpatient monitoring with an elevated CHADSVASc score and acceptable bleeding risk?
1 Answer available
How frequently should outpatient mobile cardiac telemetry be ordered following resolution of post-CABG-related atrial fibrillation for patients off anticoagulation?
1 Answer available
In what situations/patient population would you consider placing an implantable cardiac monitor in favor of external monitors for long-term dynamic monitoring of atrial fibrillation?
What are the real-life implications of the MONITOR-AF study to the routine management of AF?
1 Answer available
What is your loading dose goal and typical loading regimen for PO amiodarone in patients with atrial fibrillation?
Do you include the amount of IV amiodarone already administered as part of the loading dose? 
4 Answers available
Is there a particular PVC/NSVT burden on inpatient telemetry in which you would consider discharging a patient with a LifeVest post-STEMI with newly reduced LVEF <35% while optimizing GDMT?
1 Answer available
How do you calculate QTc intervals in patients being admitted for AAD drug loading who remain in atrial fibrillation or atrial flutter?
1 Answer available
What are your top takeaways from AHA 2023?
4 Answers available
What burden of PVCs/NSVT in an inpatient post-MI cardiomyopathy patient would prompt an EP study-guided ICD implantation prior to discharge?
1 Answer available
Do you think that home INR monitoring is a feasible option for elderly, frail patients with atrial fibrillation on VKA treatment, given variations in socioeconomic status and access to care?
2 Answers available
Do you consider bleeding risk in elderly, frail patients with atrial fibrillation to be similar for all NOACs?
In FRAIL-AF, participants were switched from VKA to dabigatran, rivaroxaban, apixaban, and edoxaban.
2 Answers available
Given recent trials for the management of atrial fibrillation with an early ablation strategy (for example, EAST-AFNET 4, EARLY-AF, PROGRESSIVE-AF, STOP-AF), what is your approach to determining the appropriate timing for ablation in patients with atrial fibrillation?
And how do patient characteristics affect your decisions?
5 Answers available
What is a reasonable amount of ventricular arrhythmia burden on outpatient remote monitoring that would prompt consideration for VT ablation in patients with normal LV function and mild symptoms? 
1 Answer available
In what clinical context would you consider offering first time catheter ablation for symptomatic atrial fibrillation in patients with advanced heart failure, as opposed to a trial of antiarrhythmics and/or cardioversion?
2 Answers available
When would you consider proceeding with antiarrhythmic drug load concurrently with DCCV as opposed to DCCV alone in patients with new-onset atrial fibrillation?
1 Answer available
In which situations do you preferentially use an MCOT in lieu of a standard event monitor?
1 Answer available
Would you start an amiodarone load for new onset atrial fibrillation with RVR intermittently in normal sinus rhythm to further suppress AF recurrence in the acute setting?
2 Answers available
What is your approach to maintenance of sotalol in terms of drug monitoring and duration of therapy for outpatients who remain in normal sinus rhythm?
2 Answers available
What is your approach to pacemaker lead thromboses in terms of threshold for lead extraction and initiation of systemic anticoagulation?
1 Answer available
What is your outpatient approach to patients with new-onset paroxysmal atrial fibrillation in the setting of acute illness but who are otherwise asymptomatic with normal sinus rhythm post-hospital discharge?
Specifically, what is your approach to outpatient monitoring to assess atrial fibrillation burden for patients with CHADS2Vasc score>2?
2 Answers available
Would you consider a primary prevention ICD in a patient with hypertrophic cardiomyopathy and non-sustained ventricular tachycardia, in the absence of any other high risk predictors for sudden cardiac death?
2 Answers available
What is your preferred pharmacologic agent for recurrent VT suppression in arrhythmogenic right ventricular cardiomyopathy?
1 Answer available
What percentage of patients with non-sustained focal atrial tachycardia detected on an outpatient Holter develop paroxysmal atrial fibrillation, and how should we identify and treat patients at the highest risk of progressing to PAF?
2 Answers available
When would you consider discharging post-TAVR patients on outpatient mobile cardiac telemetry with baseline right bundle branch block without further signs of conduction abnormalities 24-48 hours after the procedure, given risk of developing later-onset conduction abnormalities?
And if so, what is a reasonable length of time for outpatient cardiac monitoring?
2 Answers available
How do you re-stratify patients with a primary prevention ICD in need of a generator change if their LVEF has improved to >40% and they have not previously required any device therapies?
1 Answer available
When would you consider implantable loop recorders for athletes with nonspecific complaints of palpitations/dizziness, without known history of arrhythmias?
1 Answer available
How would you choose between left bundle pacing and CRT-P in a patient with a new high-degree AV block and pre-existing reduced LVEF, who does not otherwise meet the criteria for CRT-D?
(Assuming that the patient would require V-pacing almost all the time)
1 Answer available
What is your preferred rate control agent for atrial fibrillation with rapid ventricular rate, and why?
1 Answer available
Would you empirically elective to anticoagulate patients with a remote (i.e. >10 year) history of paroxysmal atrial fibrillation presenting with newly diagnosed CVA, presumed cardioembolic in etiology, without any documented recurrence of AF?
3 Answers available


Papers discussed in this category

J Am Coll Cardiol, 2019 Jan 28
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
Stroke, 2019-06
Perioperative/Postoperative Atrial Fibrillation and Risk of Subsequent Stroke and/or Mortality.
J Am Coll Cardiol, 2014 Mar 28
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.
N Engl J Med, 2019 Mar 18
Early or Delayed Cardioversion in Recent-Onset Atrial Fibrillation.
JACC Cardiovasc Interv, 2017 Jul 19
Clinical Impact of Baseline Right Bundle Branch Block in Patients Undergoing Transcatheter Aortic Valve Replacement.
Struct Heart, 2022 Mar 17
Risk Stratification and Management of Advanced Conduction Disturbances Following TAVI in Patients With Pre-Existing RBBB.
J Am Coll Cardiol, 2019 Aug 27
Management of Conduction Disturbances Associated With Transcatheter Aortic Valve Replacement: JACC Scientific Expert Panel.
Heart rhythm, 2019-11
2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy.
Heart Rhythm, 2015 Sep 30
Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with β1-selective β-blockers in patients with catecholaminergic polymorphic ventricular tachycardia.
J Am Coll Cardiol, 2009 Aug 25
The year in review of clinical cardiac electrophysiology.
Circulation, 1992 Jul
Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia.
Circulation, 2020 Dec 17
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Herz, 2014 Dec
[The 2014 ESC guidelines on the diagnosis and management of hypertrophic cardiomyopathy : what is new?].
J Am Coll Cardiol, 2018 Nov 06
2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society.
N Engl J Med, 2013 Apr 25
Biventricular pacing for atrioventricular block and systolic dysfunction.
Circulation, 2022 Apr 01
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Journal of the American College of Cardiology, 2013-07-23
Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation.
Lancet, 2021 Aug 27
Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial.
N Engl J Med, 2018 Feb 01
Catheter Ablation for Atrial Fibrillation with Heart Failure.
Cardiovasc Drugs Ther, 2021 Sep 07
Is It Safe (and When) to Stop Oral Anticoagulation After Ablation for Atrial fibrillation? (Do We Have Enough Evidence to Solve the Dilemma?).
Journal of the American College of Cardiology, 2014-09-09
Reply: Ejection fraction may improve but the scar still exists! The risk may be lower but not zero.
J Am Coll Cardiol, 2014 Apr 09
Appropriateness of primary prevention implantable cardioverter-defibrillators at the time of generator replacement: are indications still met?
JAMA, 2001-05-09
Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.
The American journal of cardiology, 2015-12-15
Frequent Atrial Premature Complexes and Their Association With Risk of Atrial Fibrillation.
Journal of electrocardiology, 2018
Frequent premature atrial complexes as a predictor of atrial fibrillation: Systematic review and meta-analysis.
J Am Coll Cardiol, 2023 Apr 04
Early Lead Extraction for Infected Implanted Cardiac Electronic Devices: JACC Review Topic of the Week.
Heart rhythm, 2020 Jul 25
Clinical significance of myocardial scar in patients with frequent premature ventricular complexes undergoing catheter ablation.
JACC. Clinical electrophysiology, 2022 Apr 28
Short-Coupled Idiopathic Ventricular Fibrillation: A Literature Review With Extended Follow-Up.
The New England journal of medicine, 2000-06-29
Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators.
The New England journal of medicine, 2011-09-15
Apixaban versus warfarin in patients with atrial fibrillation.
The New England journal of medicine, 2011 Aug 10
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
The New England journal of medicine, 2009 Aug 30
Dabigatran versus warfarin in patients with atrial fibrillation.
Circulation, 2011 Jul 25
Mobile thrombus on device leads in patients undergoing ablation: identification, incidence, location, and association with increased pulmonary artery systolic pressure.
The New England journal of medicine, 2023 Aug 27
Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation.
JACC. Clinical electrophysiology, 2021 Feb 24
Atrial Fibrillation Burden and Clinical Outcomes in Heart Failure: The CASTLE-AF Trial.
Circulation, 2023 Nov 13
Sudden Cardiac Death in National Collegiate Athletic Association Athletes: A 20-Year Study.
Circulation, 2023 Nov 11
Arrhythmic Risk In Biventricular Pacing Compared with Left Bundle Branch Area Pacing: Results From The International LBBAP Collaborative Study (I-CLAS).
Circulation. Cardiovascular quality and outcomes, 2023 Nov 06
Off-Label Dosing of Direct Oral Anticoagulants Among Inpatients with Atrial Fibrillation in the United States.
American heart journal, 2017 Apr 24
Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial.
The New England journal of medicine, 2023 Nov 11
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
American heart journal, 2023 Mar 25
Screening for peripartum cardiomyopathies using artificial intelligence in Nigeria (SPEC-AI Nigeria): Clinical trial rationale and design.
JAMA, 2023 Nov 11
Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial.
The Journal of innovations in cardiac rhythm management, 2020 May 15
Navigating Challenging Left Ventricular Lead Placements for Cardiac Resynchronization Therapy.
Cardiology, 2021 Nov 29
Strategy for Failed Transvenous Left-Ventricular Lead Placement in Cardiac Resynchronization Therapy: Surrender or Struggle?
The New England journal of medicine, 2023 Aug 25
Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes.
Journal of the American College of Cardiology, 1998-07
Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications.
European heart journal, 2017-05-01
Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT.
Heart rhythm, 2019-01
Identification of paroxysmal atrial fibrillation subtypes in over 13,000 individuals.
Pacing and clinical electrophysiology : PACE, 2019-07
Reactive atrial-based antitachycardia pacing therapy reduces atrial tachyarrhythmias.
Heart rhythm, 2015 Apr 11
New-generation atrial antitachycardia pacing (Reactive ATP) is associated with reduced risk of persistent or permanent atrial fibrillation in patients with bradycardia: Results from the MINERVA randomized multicenter international trial.
Circulation, 2023 Nov 30
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
The New England journal of medicine, 2023 Nov 12
Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation.
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2012 Mar
Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents.
The New England journal of medicine, 1991-03-21
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2022 Apr 02
Propafenone use in coronary artery disease patients undergoing atrial fibrillation ablation.
Journal of clinical medicine, 2021 Apr 02
Flecainide How and When: A Practical Guide in Supraventricular Arrhythmias.
American heart journal, 2020 Oct 13
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction.
The New England journal of medicine, 2024 Apr 07
Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock.
Circulation, 2016-12-13
Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I).
American heart journal, 2022 May 17
Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial.
The New England journal of medicine, 2024 Apr 06
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.

Related Topics in Cardiology

Copyright © 2024 theMednet
All Rights Reserved.